TIM3 comes of age as an inhibitory receptor

Y Wolf, AC Anderson, VK Kuchroo - Nature Reviews Immunology, 2020 - nature.com
T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM
family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and …

[HTML][HTML] Tim-3 finds its place in the cancer immunotherapy landscape

N Acharya, C Sabatos-Peyton… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
The blockade of immune checkpoint receptors has made great strides in the treatment of
major cancers, including melanoma, Hodgkin's lymphoma, renal, and lung cancer. However …

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy

R Yang, L Sun, CF Li, YH Wang, J Yao, H Li… - Nature …, 2021 - nature.com
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell
differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion …

Cardiovascular toxicities associated with immune checkpoint inhibitors

JR Hu, R Florido, EJ Lipson, J Naidoo… - Cardiovascular …, 2019 - academic.oup.com
Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been
reported in case series but have been underappreciated due to their recent emergence …

Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation

AC Anderson, N Joller, VK Kuchroo - Immunity, 2016 - cell.com
Co-inhibitory receptors, such as CTLA-4 and PD-1, have an important role in regulating T
cell responses and have proven to be effective targets in the setting of chronic diseases …

Tim‐3 and its role in regulating anti‐tumor immunity

M Das, C Zhu, VK Kuchroo - Immunological reviews, 2017 - Wiley Online Library
Immunotherapy is being increasingly recognized as a key therapeutic modality to treat
cancer and represents one of the most exciting treatments for the disease. Fighting cancer …

TIM-3: An update on immunotherapy

L Zhao, S Cheng, L Fan, B Zhang, S Xu - International …, 2021 - Elsevier
T cell immunoglobulin and mucin domain 3 (TIM-3) was originally found to be expressed on
the surface of Th1 cells, acting as a negative regulator and binding to the ligand galectin-9 to …

Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting

B Chaudhary, E Elkord - Vaccines, 2016 - mdpi.com
Recent years have seen significant efforts in understanding and modulating the immune
response in cancer. In this context, immunosuppressive cells, including regulatory T cells …

[HTML][HTML] Immune-based therapies for hepatocellular carcinoma

DJ Pinato, N Guerra, P Fessas, R Murphy, T Mineo… - Oncogene, 2020 - nature.com
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death.
The immune-rich contexture of the HCC microenvironment makes this tumour an appealing …

Emerging targets in cancer immunotherapy

S Burugu, AR Dancsok, TO Nielsen - Seminars in cancer biology, 2018 - Elsevier
The first generation of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1)
targeted natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor …